Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126452381 | 12645238 | 1 | I | 20160801 | 20160811 | 20160811 | EXP | HR-TEVA-681696ACC | TEVA | DABELIC N,MATESA N,JUKIC T,SOLDIC Z,KUST D,PRGOMET A. PRIMARY FIBROSARCOMA OF THE THYROID GLAND: CASE REPORT. ACTA CLINICA CROATICA. 2016 JAN 01;172-175. | 59.00 | YR | M | Y | 0.00000 | 20160811 | OT | HR | HR |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126452381 | 12645238 | 1 | PS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Unknown | U | 63097 | ||||||||||
126452381 | 12645238 | 2 | SS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Unknown | U | 63097 | INJECTION |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126452381 | 12645238 | 1 | Fibrosarcoma |
126452381 | 12645238 | 2 | Fibrosarcoma |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126452381 | 12645238 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126452381 | 12645238 | Febrile neutropenia | |
126452381 | 12645238 | Off label use | |
126452381 | 12645238 | Product use issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126452381 | 12645238 | 2 | 200402 | 0 |